50% Imaging Error Rate in Clinical Trials Discussed by Expert Panelists from 5 NCI-Designated Cancer Centers

CHICAGO, IL / ACCESSWIRE / July 23, 2024 / Yunu, a provider of medical research technology and services, recently hosted a panel at the AACI Cancer Research Innovation symposium. The discussion highlighted alarming error and non-compliance rates in imaging assessments during clinical trials across multiple sites.

Panelists discussed an abstract revealing that half of all imaging assessments had non-conformities. Findings showed error rates of 25%, 30%, and 50% in oncology trials, which were reduced to below 2% using Yunu's trial imaging platform. These errors lead to delayed trial activation, incorrect patient enrollments, increased costs, audit findings, and data loss. One study noted the financial impact of these errors surpassed all imaging costs of the trials.

Yunu's platform enhances trial imaging compliance, offering improved workflow efficiencies, team acceleration, resource sharing, and audit-ready data management. CEO Jeff Sorenson stated that the current manual error-prone processes are ineffective, emphasizing the need for advanced solutions like Yunu's platform.